Form 4: Pelthos Therapeutics Director Todd Davis Reports Significant Share Acquisition Following Merger and Reverse Stock Split

Pelthos Therapeutics Inc. Director and 10% owner Todd C. Davis reported the indirect acquisition of over 4.6 million common shares through Ligand Pharmaceuticals Inc. following a 1-for-10 reverse stock split and a merger transaction.

Summary

• Todd C. Davis, a Director and 10% Owner of Pelthos Therapeutics Inc. (PTHS), reported changes in beneficial ownership.
• The reported numbers reflect a 1-for-10 reverse stock split effected by Pelthos Therapeutics Inc. on July 1, 2025.
• On July 1, 2025, Davis indirectly acquired 1,500,000 shares of Pelthos Common Stock at a conversion price of $10 per share, resulting from the conversion of 15,000 shares of Series A Convertible Preferred Stock.
• Also on July 1, 2025, Davis indirectly acquired 3,127,868 shares of Pelthos Common Stock through the acquisition of 31,278.681 shares of Series A Convertible Preferred Stock.
• This acquisition of preferred stock was in exchange for shares of LNHC, Inc. common stock, as part of a merger where CHRO Merger Sub, Inc. (a wholly-owned subsidiary of Pelthos) merged with and into LNHC, Inc. (a wholly-owned subsidiary of Ligand Pharmaceuticals Inc.), with LNHC continuing as a wholly-owned subsidiary of Pelthos.
• The merger agreement was dated April 16, 2025.
• Davis's beneficial ownership is indirect, through Ligand Pharmaceuticals Inc., where he serves as Chief Executive Officer and a board member. He disclaims beneficial ownership except to the extent of his pecuniary interest.
• The Series A convertible preferred stock is convertible at any time, has no expiration date, and is subject to a contractual limitation preventing conversion if it would result in beneficial ownership exceeding 49.9% of outstanding common stock.

Sentiment

Score: 7

Explanation: The filing reports the completion of a merger and a significant increase in indirect beneficial ownership by a key insider, which generally signals positive strategic alignment and confidence, despite being a routine disclosure.

Positives

• Completion of the merger between Pelthos's subsidiary and Ligand's subsidiary, streamlining corporate structure.
• Significant indirect acquisition of Pelthos common stock by a director and 10% owner, Todd C. Davis, potentially signaling confidence in the company's future.

Future Outlook

No explicit forward-looking statements or guidance are provided in this Form 4 filing beyond the completion of the merger.

Industry Context

The transaction reflects ongoing consolidation and strategic realignments common within the biotechnology and pharmaceutical sectors, where mergers and acquisitions are frequently used to expand pipelines, acquire technologies, or optimize corporate structures.

Related Party Transactions

• The acquisition of Series A Convertible Preferred Stock by Todd C. Davis, CEO and board member of Ligand Pharmaceuticals Inc., in exchange for shares of LNHC, Inc. (a wholly-owned subsidiary of Ligand) as part of a merger with Pelthos's subsidiary, constitutes a related party transaction given Davis's dual roles and Ligand's relationship with Pelthos.

Stakeholder Impact

• Shareholders: The reverse stock split impacts the number of shares outstanding and per-share metrics. The merger and the resulting ownership structure, particularly the significant indirect stake held by Ligand (via Todd Davis), could influence future strategic direction and shareholder value.
• Employees: The merger of LNHC into Pelthos's subsidiary could have implications for employees of LNHC, potentially involving integration or restructuring.

Key Dates

Keywords

Pelthos Therapeutics, PTHS, Ligand Pharmaceuticals, LNHC, Todd C. Davis, SEC Form 4, insider ownership, beneficial ownership, stock split, reverse stock split, merger, corporate transaction, convertible preferred stock, director, 10% owner